Lineage Cell Therapeutics
LCTX
LCTX
106 hedge funds and large institutions have $130M invested in Lineage Cell Therapeutics in 2018 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 107 → 106 (-1)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
Holders
106
Holding in Top 10
2
Calls
$215K
Puts
$78K
Top Buyers
| 1 | +$1.24M | |
| 2 | +$448K | |
| 3 | +$437K | |
| 4 |
State Street
Boston,
Massachusetts
|
+$209K |
| 5 |
JG
Jefferies Group
New York
|
+$202K |
Top Sellers
| 1 | -$469K | |
| 2 | -$300K | |
| 3 | -$220K | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$214K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$192K |